Reference
Medicines and Healthcare products Regulatory Agency (UK). Carfilzomib (Kyprolis): risk of reactivation of hepatitis B virus. Drug Safety Update 13: No. 4, Nov 2019. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/847878/Nov-2019-PDF.pdf
Rights and permissions
About this article
Cite this article
Risk of hepatitis B reactivation with carfilzomib. Reactions Weekly 1782, 4 (2019). https://doi.org/10.1007/s40278-019-72173-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-72173-x